Luteolin mitigates proliferative vitreoretinopathy through inhibition of ERK1/2 signaling and epithelial–mesenchymal transition

Key Points

• Luteolin mitigates proliferative vitreoretinopathy (PVR) through significant inhibition of epithelial-mesenchymal transition.
• In vitro studies indicate reduced RPE cell migration, correlating with a decrease in ERK1/2 signaling activity.
• The findings suggest that luteolin has protective effects on retinal pigment epithelial cells during PVR development.
• This work highlights luteolin’s potential as a therapeutic agent, requiring further studies to confirm efficacy.